Biomerica Enters Service Agreement with Life Sciences Company, Contract Exceeds $1.75M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Biomerica announced it has entered into a master services agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays. The engagement carries an initial contract development target fee of over $1.75M, to be earned across multiple statements of work under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed. The MSA establishes an initial three-year term with automatic one-year renewals. All development work will be performed at Biomerica's FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue will be recognized on a milestone-completion basis as individual SOW deliverables are accepted.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRA
About BMRA
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biomerica to Present IBS Therapy at Digestive Disease Week 2026
- Data Presentation: Biomerica's inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week 2026, reflecting the growing interest in personalized, non-pharmacologic dietary management strategies within the gastroenterology community, potentially enhancing the company's influence in the IBS market.
- Clinical Study Results: The study builds on a multicenter, double-blind, placebo-controlled trial, demonstrating that 59.6% of patients in the treatment group achieved significant abdominal pain reduction after eliminating identified trigger foods, compared to 42.1% in the control group, indicating the clinical effectiveness of the therapy.
- Significant Market Potential: With IBS affecting an estimated 30 to 45 million adults in the U.S., Biomerica's inFoods® IBS addresses a significant unmet clinical need within a $30 billion total addressable market by providing targeted dietary recommendations based on individual food triggers.
- Enhanced Industry Influence: Participation in Digestive Disease Week in Chicago attracts top medical experts globally, which not only boosts Biomerica's brand visibility but also potentially paves the way for future collaborations and market expansion.
See More
Biomerica's IBS Test Receives Medicare Coverage Confirmation
- Medicare Coverage Confirmation: Biomerica's inFoods® IBS test has received confirmation from the Medicare Administrative Contractor that claims will be reviewed on an individual basis, with eligible claims potentially receiving a $300 payment, marking a crucial step towards revenue growth for the company.
- Streamlined Claims Process: Claims for the test will be processed through Biomerica's CLIA-certified laboratory, ensuring centralized handling and review of claims, thereby enhancing the company's competitiveness in the healthcare market.
- Clinical Evidence Support: The inFoods® IBS test demonstrated significant clinical efficacy in a multicenter randomized controlled trial, with 59.6% of patients in the treatment group achieving FDA endpoints for abdominal pain reduction, strengthening the rationale for Medicare claims.
- Significant Market Potential: IBS affects 10-15% of U.S. adults, particularly over 20% of the elderly population, providing a strong demand foundation that is expected to generate substantial revenue opportunities for Biomerica.
See More
Biomerica Reports Decline in Q3 Revenue Amid Restructuring Efforts
- Financial Decline: Biomerica's net sales for Q3 FY2026 fell to $0.98 million from $1.12 million year-over-year, reflecting a 12.5% decrease that highlights the challenges faced during the company's transition, potentially impacting future market confidence.
- Widening Net Loss: The net loss for the third quarter widened to $1.31 million from $1.16 million in the prior year, although the per-share loss narrowed by 37% to $0.92, indicating efforts in cost control that may lay the groundwork for future profitability.
- Strategic Restructuring: CEO Zack Irani stated that the company is restructuring around higher-margin, diagnostically-driven products and a growing Contract Development and Manufacturing Organization (CDMO) services business, suggesting that while short-term revenues are affected, the long-term strategy may enhance market competitiveness.
- Stock Price Volatility: BMRA's stock has traded between $1.87 and $4.88 over the past year, closing at $2.01 on Monday, down 2.80%, but rising 1.44% to $2.11 in after-hours trading, indicating market interest in the company's future transformation.
See More
Biomerica Reports Increased Q3 Losses Amid Revenue Decline
- Financial Performance Decline: Biomerica reported a net loss of $1.31 million for Q3 of fiscal 2026, an increase from $1.16 million in the same quarter last year, indicating pressure on the company's profitability.
- Revenue Drop: The revenue for the third quarter was $0.99 million, reflecting an 11.6% year-over-year decline, which suggests challenges in market competitiveness that could impact future liquidity and investor confidence.
- Market Reaction: Due to the disappointing financial results, investors may adopt a cautious stance regarding Biomerica's growth prospects, potentially leading to negative impacts on the stock price and increasing market uncertainty.
- Need for Strategic Adjustment: In light of ongoing losses and declining revenues, the company may need to reassess its market strategies and operational efficiencies to restore profitability and attract investment in a highly competitive environment.
See More
Biomerica Reports Q3 Fiscal 2026 Financial Results with Key Highlights
- Clinical Data Highlights: Among patients using inFoods®IBS, 59.4% achieved a ≥30% reduction in abdominal pain and 68.1% achieved a ≥30% reduction in bloating, based on FDA-recognized responder endpoints, indicating the product's effectiveness in alleviating IBS symptoms and potentially driving future sales growth.
- Medicare Payment Rate Established: CMS has set a national Medicare payment rate of $300 for the inFoods®IBS test, effective January 1, 2026, marking a significant milestone that will help expand patient access to the product and enhance market penetration.
- European Market Growth: Revenue from European customers grew 45% year-over-year in the third quarter, increasing from $198,000 to $287,000, reflecting Biomerica's strengthening commercial momentum in the region, while hp+detect™ received UK regulatory registration, laying the groundwork for future commercial sales.
- R&D Expenses Reduced: Year-to-date R&D expenses decreased by 24%, from $771,000 to $583,000, reflecting effective resource allocation as the company transitions towards commercialization, with expectations for further margin improvement.
See More
Biomerica Secures First Commercial Order for Hp Detect Test
- First Commercial Order: Biomerica announced it has secured its first commercial order for the Hp Detect H. pylori test from a major European lab chain, specifically targeting the UK market, marking a significant step in the company's expansion into European commercialization.
- Regulatory Approval Context: This order follows the MHRA clearance obtained in February 2026, demonstrating the company's capability to meet stringent regulatory requirements, thereby enhancing its competitive position in the European market.
- Market Expansion Potential: The order is expected to support further distribution partnerships in the U.S. and EU markets, driving the company's market penetration and sales growth on a global scale.
- Stock Price Reaction: Following this announcement, Biomerica's shares rose by 4.00%, reflecting investor optimism regarding the company's future growth potential.
See More
Biomerica to Present IBS Therapy at Digestive Disease Week 2026
- Data Presentation: Biomerica's inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week 2026, reflecting the growing interest in personalized, non-pharmacologic dietary management strategies within the gastroenterology community, potentially enhancing the company's influence in the IBS market.
- Clinical Study Results: The study builds on a multicenter, double-blind, placebo-controlled trial, demonstrating that 59.6% of patients in the treatment group achieved significant abdominal pain reduction after eliminating identified trigger foods, compared to 42.1% in the control group, indicating the clinical effectiveness of the therapy.
- Significant Market Potential: With IBS affecting an estimated 30 to 45 million adults in the U.S., Biomerica's inFoods® IBS addresses a significant unmet clinical need within a $30 billion total addressable market by providing targeted dietary recommendations based on individual food triggers.
- Enhanced Industry Influence: Participation in Digestive Disease Week in Chicago attracts top medical experts globally, which not only boosts Biomerica's brand visibility but also potentially paves the way for future collaborations and market expansion.
See More
Biomerica's IBS Test Receives Medicare Coverage Confirmation
- Medicare Coverage Confirmation: Biomerica's inFoods® IBS test has received confirmation from the Medicare Administrative Contractor that claims will be reviewed on an individual basis, with eligible claims potentially receiving a $300 payment, marking a crucial step towards revenue growth for the company.
- Streamlined Claims Process: Claims for the test will be processed through Biomerica's CLIA-certified laboratory, ensuring centralized handling and review of claims, thereby enhancing the company's competitiveness in the healthcare market.
- Clinical Evidence Support: The inFoods® IBS test demonstrated significant clinical efficacy in a multicenter randomized controlled trial, with 59.6% of patients in the treatment group achieving FDA endpoints for abdominal pain reduction, strengthening the rationale for Medicare claims.
- Significant Market Potential: IBS affects 10-15% of U.S. adults, particularly over 20% of the elderly population, providing a strong demand foundation that is expected to generate substantial revenue opportunities for Biomerica.
See More
Biomerica Reports Decline in Q3 Revenue Amid Restructuring Efforts
- Financial Decline: Biomerica's net sales for Q3 FY2026 fell to $0.98 million from $1.12 million year-over-year, reflecting a 12.5% decrease that highlights the challenges faced during the company's transition, potentially impacting future market confidence.
- Widening Net Loss: The net loss for the third quarter widened to $1.31 million from $1.16 million in the prior year, although the per-share loss narrowed by 37% to $0.92, indicating efforts in cost control that may lay the groundwork for future profitability.
- Strategic Restructuring: CEO Zack Irani stated that the company is restructuring around higher-margin, diagnostically-driven products and a growing Contract Development and Manufacturing Organization (CDMO) services business, suggesting that while short-term revenues are affected, the long-term strategy may enhance market competitiveness.
- Stock Price Volatility: BMRA's stock has traded between $1.87 and $4.88 over the past year, closing at $2.01 on Monday, down 2.80%, but rising 1.44% to $2.11 in after-hours trading, indicating market interest in the company's future transformation.
See More
Biomerica Reports Increased Q3 Losses Amid Revenue Decline
- Financial Performance Decline: Biomerica reported a net loss of $1.31 million for Q3 of fiscal 2026, an increase from $1.16 million in the same quarter last year, indicating pressure on the company's profitability.
- Revenue Drop: The revenue for the third quarter was $0.99 million, reflecting an 11.6% year-over-year decline, which suggests challenges in market competitiveness that could impact future liquidity and investor confidence.
- Market Reaction: Due to the disappointing financial results, investors may adopt a cautious stance regarding Biomerica's growth prospects, potentially leading to negative impacts on the stock price and increasing market uncertainty.
- Need for Strategic Adjustment: In light of ongoing losses and declining revenues, the company may need to reassess its market strategies and operational efficiencies to restore profitability and attract investment in a highly competitive environment.
See More
Biomerica Reports Q3 Fiscal 2026 Financial Results with Key Highlights
- Clinical Data Highlights: Among patients using inFoods®IBS, 59.4% achieved a ≥30% reduction in abdominal pain and 68.1% achieved a ≥30% reduction in bloating, based on FDA-recognized responder endpoints, indicating the product's effectiveness in alleviating IBS symptoms and potentially driving future sales growth.
- Medicare Payment Rate Established: CMS has set a national Medicare payment rate of $300 for the inFoods®IBS test, effective January 1, 2026, marking a significant milestone that will help expand patient access to the product and enhance market penetration.
- European Market Growth: Revenue from European customers grew 45% year-over-year in the third quarter, increasing from $198,000 to $287,000, reflecting Biomerica's strengthening commercial momentum in the region, while hp+detect™ received UK regulatory registration, laying the groundwork for future commercial sales.
- R&D Expenses Reduced: Year-to-date R&D expenses decreased by 24%, from $771,000 to $583,000, reflecting effective resource allocation as the company transitions towards commercialization, with expectations for further margin improvement.
See More
Biomerica Secures First Commercial Order for Hp Detect Test
- First Commercial Order: Biomerica announced it has secured its first commercial order for the Hp Detect H. pylori test from a major European lab chain, specifically targeting the UK market, marking a significant step in the company's expansion into European commercialization.
- Regulatory Approval Context: This order follows the MHRA clearance obtained in February 2026, demonstrating the company's capability to meet stringent regulatory requirements, thereby enhancing its competitive position in the European market.
- Market Expansion Potential: The order is expected to support further distribution partnerships in the U.S. and EU markets, driving the company's market penetration and sales growth on a global scale.
- Stock Price Reaction: Following this announcement, Biomerica's shares rose by 4.00%, reflecting investor optimism regarding the company's future growth potential.
See More
